LYM
MCID: LYM017
MIFTS: 71

Lyme Disease (LYM)

Categories: Infectious diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Lyme Disease

MalaCards integrated aliases for Lyme Disease:

Name: Lyme Disease 12 76 53 25 59 55 43 3 44 15 73
Lyme Borreliosis 12 53 25 59 15
Lyme Neuroborreliosis 12 55 44 73
Neuroborreliosis 12 73
Borreliosis 53 55
Infection Due to Borrelia Burgdorferi Sensu Lato 25
Infection by Borrelia Burgdorferi 25
Borrelia Burgdorferi Infection 25
Neurological Lyme Disease 12
B. Burgdorferi Infection 25
Bannworth's Syndrome 12
Borrelia Infections 73
Bannwarth Syndrome 12
Borreliosis, Lyme 25
Lym 76

Characteristics:

Orphanet epidemiological data:

59
lyme disease
Inheritance: Not applicable; Prevalence: >1/1000 (Europe),1-5/10000 (France); Age of onset: All ages;

Classifications:



Summaries for Lyme Disease

MedlinePlus : 43 Lyme disease is a bacterial infection you get from the bite of an infected tick. The first symptom is usually a red rash, which may look like a bull's eye. But not all people with Lyme disease have a rash. As the infection spreads to other parts of the body, you may have A fever A headache Body aches A stiff neck Fatigue Lyme disease can be hard to diagnose because many of its symptoms are like those of the flu and other diseases. And you may not have noticed a tick bite. Your health care provider will look at your symptoms and medical history to figure out whether you have Lyme disease. Lab tests may not always give a clear answer until you have been infected for at least a few weeks. Antibiotics can cure most cases of Lyme disease. The sooner treatment begins, the quicker and more complete the recovery. After treatment, some patients may still have muscle or joint aches and nervous system symptoms. This is called post-treatment Lyme disease syndrome (PTLDS). Long-term antibiotics have not been shown to help with PTLDS. However, there are ways to help with the symptoms of PTLDS, and most patients do get better with time. NIH: National Institute of Allergy and Infectious Diseases

MalaCards based summary : Lyme Disease, also known as lyme borreliosis, is related to autoimmune inner ear disease and relapsing fever, and has symptoms including fever, fatigue and headache. An important gene associated with Lyme Disease is TLR2 (Toll Like Receptor 2), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Doxycycline and Ceftriaxone have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and heart, and related phenotypes are muscle weakness and nausea and vomiting

Disease Ontology : 12 A primary bacterial infectious disease that results in infection, has material basis in Borrelia burgdorferi, which is transmitted by blacklegged tick (Ixodes scapularis) or transmitted by western blacklegged tick (Ixodes pacificus). The infection has symptom fever, has symptom headache, has symptom fatigue, and has symptom skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system.

Genetics Home Reference : 25 Lyme disease is an infectious disease caused by Borrelia burgdorferi bacteria. The bacteria are transferred to humans by tick bite, specifically by blacklegged ticks (commonly known as deer ticks). The condition is named for the location in which it was first described, the town of Lyme, Connecticut.

NIH Rare Diseases : 53 Lyme disease is the most common tickborne infectious disease in the United States. Early signs and symptoms of the condition include fever, chills, muscle pain, headache, and joint pain. As the condition progresses, affected people may experience heart problems, Bell's palsy, arthritis, abnormal muscle movement, speech problems and cognitive (thinking) abnormalities. Please visit the Center for Disease Control and Prevention's Web site for a more comprehensive list of symptoms. Lyme disease is caused by the bacterium Borrelia burgdorferi, which is transmitted to humans through the bite of infected blacklegged ticks. Certain features of the condition, including whether or not an affected person will develop medication-resistant chronic arthritis, is thought to be influenced by genetic factors (certain human leukocyte antigen genes). Treatment generally includes antibiotics to address the bacterial infection and other medications (i.e. pain medications) to relieve symptoms.

CDC : 3 Lyme disease is caused by the bacterium Borrelia burgdorferi and is transmitted to humans through the bite of infected blacklegged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system. Lyme disease is diagnosed based on symptoms, physical findings (e.g., rash), and the possibility of exposure to infected ticks.  Laboratory testing is helpful if used correctly and performed with validated methods. Most cases of Lyme disease can be treated successfully with a few weeks of antibiotics. Steps to prevent Lyme disease include using insect repellent, removing ticks promptly, applying pesticides, and reducing tick habitat. The ticks that transmit Lyme disease can occasionally transmit other tickborne diseases as well.

Wikipedia : 76 Jean Baptiste Point du Sable (before 1750 ? 1818) is honored as the first permanent non-Native-American... more...

Related Diseases for Lyme Disease

Diseases related to Lyme Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 488)
# Related Disease Score Top Affiliating Genes
1 autoimmune inner ear disease 31.7 MMP9 TNF
2 relapsing fever 30.5 CFH CRP TNF
3 choroiditis 30.2 CFH TNF
4 chronic fatigue syndrome 30.1 IL1B IL6 TNF
5 myocarditis 30.1 CD40LG IL6 TNF
6 acute transverse myelitis 30.0 IL6 MMP9
7 myelitis 30.0 IL17A IL6 TNF
8 pertussis 30.0 IL1B IL6 TNF
9 cytomegalovirus infection 30.0 IL1B IL6 TNF
10 legionellosis 29.9 IL1B TLR2 TNF
11 arthritis 29.9 IL17A IL1B IL6 MMP9 TNF
12 multifocal choroiditis 29.9 CFH TNF
13 complex regional pain syndrome 29.9 IL1B IL6 TNF
14 prosthetic joint infection 29.9 IL1B TLR2
15 glomerulonephritis 29.9 C3 CD40LG CFH IL1B
16 connective tissue disease 29.9 CD40LG HSPD1 IL6 TNF
17 scleritis 29.8 MMP9 TNF
18 transverse myelitis 29.7 IL17A IL6 MMP9 TNF
19 viral infectious disease 29.7 CD40LG IL1B IL6 TNF
20 brucellosis 29.6 CD40LG CRP IL6 TNF
21 q fever 29.6 IL1B IL6 TLR1 TLR2 TNF
22 chronic meningitis 29.6 CRP MMP9
23 otitis media 29.5 IL1B IL6 TLR2 TNF
24 stromal keratitis 29.5 IL17A IL6 TNF
25 common variable immunodeficiency 29.4 CD40LG IL6 TLR2 TNF
26 vasculitis 29.4 CD40LG CRP TNF
27 chlamydia 29.4 CRP HSPD1 IL1B IL6 TLR2 TNF
28 temporal arteritis 29.4 CRP IL6 TNF
29 neurosyphilis 29.4 IL17A TLR1 TLR2 TLR6
30 pericarditis 29.4 CRP IL1B IL6 TNF
31 juvenile rheumatoid arthritis 29.3 CRP IL1B IL6 TNF
32 rheumatic disease 29.3 CD40LG CRP IL1B TNF
33 spondyloarthropathy 29.3 IL17A IL6 TNF
34 exanthem 29.3 CRP IL6 TNF
35 toxoplasmosis 29.3 CD40LG IL1B IL6 TLR2 TNF
36 tropical spastic paraparesis 29.3 IL17A IL6 MMP9
37 louse-borne relapsing fever 29.3 CFHR1 CRP IL6 TNF
38 meningitis 29.3 CRP IL1B IL6 MMP9 TLR2 TNF
39 scrub typhus 29.2 CRP IL1B TLR2 TNF
40 multiple sclerosis 29.2 CLDN11 IL17A IL1B IL6 MMP9 TNF
41 adult-onset still's disease 29.1 CRP IL1B IL6 TNF
42 spondylitis 29.0 CRP IL17A IL6 TNF
43 spondyloarthropathy 1 28.9 CRP IL17A TNF
44 leptospirosis 28.9 CRP IL1B IL6 TLR1 TLR2 TNF
45 bacterial meningitis 28.9 CRP IL1B IL6 MMP9 TLR2 TNF
46 dilated cardiomyopathy 28.8 CRP IL17A IL1B IL6 MMP9 TNF
47 psoriatic arthritis 28.8 CRP IL17A IL1B IL6 TNF
48 myocardial infarction 28.6 CD40LG CRP IL1B IL6 MMP9 TNF
49 rheumatoid arthritis 28.6 CD40LG CRP IL17A IL1B IL6 MMP9
50 bacterial infectious disease 28.4 CRP HSPD1 IL17A IL1B IL6 TLR1

Graphical network of the top 20 diseases related to Lyme Disease:



Diseases related to Lyme Disease

Symptoms & Phenotypes for Lyme Disease

Symptoms:

12
  • fever
  • fatigue
  • headache
  • skin rash called erythema migrans

Human phenotypes related to Lyme Disease:

59 32 (show all 24)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscle weakness 59 32 occasional (7.5%) Occasional (29-5%) HP:0001324
2 nausea and vomiting 59 32 occasional (7.5%) Occasional (29-5%) HP:0002017
3 encephalitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002383
4 arthritis 59 32 frequent (33%) Frequent (79-30%) HP:0001369
5 photophobia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000613
6 fever 59 32 occasional (7.5%) Occasional (29-5%) HP:0001945
7 cranial nerve paralysis 59 32 frequent (33%) Frequent (79-30%) HP:0006824
8 fatigue 59 32 occasional (7.5%) Occasional (29-5%) HP:0012378
9 joint swelling 59 32 frequent (33%) Frequent (79-30%) HP:0001386
10 arthralgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002829
11 atrioventricular block 59 32 occasional (7.5%) Occasional (29-5%) HP:0001678
12 arrhythmia 59 32 occasional (7.5%) Occasional (29-5%) HP:0011675
13 memory impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0002354
14 myalgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003326
15 paresthesia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003401
16 amaurosis fugax 59 32 occasional (7.5%) Occasional (29-5%) HP:0100576
17 meningitis 59 32 frequent (33%) Frequent (79-30%) HP:0001287
18 insomnia 59 32 occasional (7.5%) Occasional (29-5%) HP:0100785
19 headache 59 32 occasional (7.5%) Occasional (29-5%) HP:0002315
20 uveitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000554
21 skin nodule 59 32 occasional (7.5%) Occasional (29-5%) HP:0200036
22 dermal atrophy 59 32 occasional (7.5%) Occasional (29-5%) HP:0004334
23 behavioral abnormality 59 Occasional (29-5%)
24 peripheral neuropathy 59 Occasional (29-5%)

UMLS symptoms related to Lyme Disease:


fever, pruritus

MGI Mouse Phenotypes related to Lyme Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.15 C3 CD40LG CFH CRP IL17A IL1B
2 hematopoietic system MP:0005397 10.14 C3 CD40LG CFH IL17A IL1B IL6
3 cardiovascular system MP:0005385 10.11 C3 CD40LG CFH CRP IL1B IL6
4 mortality/aging MP:0010768 10.06 C3 CD40LG CFH HSPD1 IL17A IL1B
5 endocrine/exocrine gland MP:0005379 10.03 C3 CD40LG CLDN11 IL17A IL6 TLR2
6 nervous system MP:0003631 10 C3 CD40LG CFH CLDN11 HSPD1 IL1B
7 renal/urinary system MP:0005367 9.7 C3 CD40LG CFH IL17A IL6 MMP9
8 reproductive system MP:0005389 9.61 C3 CD40LG CLDN11 HSPD1 IL6 MMP9
9 skeleton MP:0005390 9.23 C3 CD40LG IL17A IL1B IL6 MMP9

Drugs & Therapeutics for Lyme Disease

Drugs for Lyme Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 564-25-0 54671203
2
Ceftriaxone Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 73384-59-5 5479530 5361919
3
Clarithromycin Approved Phase 4 81103-11-9 84029
4
Hydroxychloroquine Approved Phase 4 118-42-3 3652
5
Cefuroxime Approved Phase 4,Not Applicable 55268-75-2 5361202 5479529
6
Penicillin V Approved, Vet_approved Phase 4 87-08-1 6869
7
Amoxicillin Approved, Vet_approved Phase 4,Not Applicable 26787-78-0 33613
8
Azithromycin Approved Phase 4,Phase 1,Phase 2 83905-01-5 55185 447043
9
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
10 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Not Applicable
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Antimalarials Phase 4,Phase 3,Phase 2,Not Applicable
15 Cytochrome P-450 Enzyme Inhibitors Phase 4,Not Applicable
16 Antitubercular Agents Phase 4,Phase 2,Not Applicable
17 Cytochrome P-450 CYP3A Inhibitors Phase 4,Not Applicable
18 Antirheumatic Agents Phase 4
19 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 cefuroxime axetil Phase 4,Not Applicable
21 penicillins Phase 4
22 Erythromycin stearate Phase 4
23 Erythromycin Estolate Phase 4
24 Erythromycin Ethylsuccinate Phase 4
25
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
26
Permethrin Approved, Investigational Phase 3 52645-53-1 40326
27 PENTA Phase 3
28 Vaccines Phase 1, Phase 2,Not Applicable
29 Immunologic Factors Phase 1, Phase 2,Not Applicable
30
Carbon monoxide Approved, Investigational Phase 1 630-08-0 281
31
Aluminum sulfate Approved Phase 1 10043-01-3
32
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
33 Gastrointestinal Agents Phase 1
34 Anti-Ulcer Agents Phase 1
35 Antacids Phase 1
36 Adjuvants, Immunologic Phase 1
37
Zidovudine Approved Not Applicable 30516-87-1 35370
38
Lopinavir Approved Not Applicable 192725-17-0 92727
39
Lamivudine Approved, Investigational Not Applicable 134678-17-4 60825
40
Didanosine Approved Not Applicable 69655-05-6 50599
41
Ritonavir Approved, Investigational Not Applicable 155213-67-5 392622
42
Stavudine Approved, Investigational Not Applicable 3056-17-5 18283
43
Ethanol Approved 64-17-5 702
44
Hydroxocobalamin Approved 13422-51-0 11953898 44475014
45
Methylcobalamin Approved, Experimental, Investigational 13422-55-4
46
Granisetron Approved, Investigational Not Applicable 109889-09-0 3510
47
Acyclovir Approved 59277-89-3 2022
48
Dopamine Approved 51-61-6, 62-31-7 681
49
Cyanocobalamin Approved, Nutraceutical 68-19-9 44176380
50
Tenofovir Experimental, Investigational Not Applicable 147127-20-6 464205

Interventional clinical trials:

(show top 50) (show all 66)
# Name Status NCT ID Phase Drugs
1 Persistent Lyme Empiric Antibiotic Study Europe Completed NCT01207739 Phase 4 Doxycycline;Clarithromycin and hydroxychloroquine;Placebo
2 Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome Completed NCT01518192 Phase 4 doxycycline;cefuroxime axetil
3 Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice Completed NCT01368341 Phase 4 Doxycycline;Phenoxymethylpenicillin;Amoxicillin
4 Aizthromycin or Clarithromycin in H-pylori Eradication Regimen Completed NCT01667692 Phase 4 azithromycin;clarithmycin
5 Study of Lyme Neuroborreliosis Completed NCT01635530 Phase 4 Doxycycline;Ceftriaxone
6 Evaluation of Cortisone Treatment in Children With Acute Facial Nerve Palsy Not yet recruiting NCT03781700 Phase 4 Prednisolone;Placebo Oral Tablet
7 Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
8 Study and Treatment of Post Lyme Disease (STOP-LD) Completed NCT00000937 Phase 3 Antibiotics
9 Lyme Disease Prevention Program Completed NCT00000432 Phase 3
10 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease Completed NCT00001101 Phase 3 ceftriaxone;doxycycline
11 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease Completed NCT00000938 Phase 3 ceftriaxone;doxycycline
12 Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever Completed NCT00237016 Phase 2, Phase 3 doxycycline treatment
13 Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis Completed NCT00138801 Phase 3 Ceftriaxone;Doxycycline
14 Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis Enrolling by invitation NCT02553473 Phase 3 Doxycycline;Placebo
15 Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes Terminated NCT00958139 Phase 3
16 A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis Unknown status NCT00591318 Phase 1, Phase 2 ceftriaxone;Normal Saline
17 Brain Imaging and Retreatment Study of Persistent Lyme Disease Completed NCT00037479 Phase 2 ceftriaxone
18 Safety, Skin and Plasma Concentration of Azithromycin Dermal Formulation Completed NCT01243008 Phase 1, Phase 2 Application of SHB001
19 Antibiotic Treatment Trial for the PANDAS/PANS Phenotype Completed NCT01617083 Phase 2 Azithromycin;Placebo
20 Phase 1/2 Lyme Vaccine Study Completed NCT01504347 Phase 1, Phase 2
21 Xenodiagnosis After Antibiotic Treatment for Lyme Disease Recruiting NCT02446626 Phase 1, Phase 2 Xenodiagnosis
22 Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study. Recruiting NCT03769194 Phase 2
23 A Clinical Trial of the Clinical Effects of Hyperbaric Oxygen Therapy in Thai Autistic Children Completed NCT00670891 Phase 1
24 Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis Active, not recruiting NCT03010228 Phase 1
25 Meditation and Stretching for Post Treatment Lyme Disease Syndrome Unknown status NCT02344537 Not Applicable
26 A School-Based Intervention to Reduce Lyme Disease Unknown status NCT00594997 Not Applicable
27 Cohort Description of Younger With AV-block Unknown status NCT03024047
28 Doxycycline and Ceftriaxone in Suspected Early Lyme Neuroborreliosis Unknown status NCT00942006 Not Applicable doxycycline;ceftriaxone
29 Searching for Persistence of Infection in Lyme Disease Completed NCT01143558 Early Phase 1
30 Culture Media for Borrelia Burgdorferi Sensu Lato Completed NCT02145754 Not Applicable
31 Analysis of Lyme Disease Lesions Completed NCT00132327
32 Sofia 2 Lyme FIA Whole Blood Clinical Study Completed NCT03238274
33 CD8 Reactivity to Microorganisms in Blood and Breast Milk Completed NCT03084614
34 Comparison of Doxycycline and Cefuroxime Axetil in Erythema Migrans Completed NCT03584919 Not Applicable doxycycline;Cefuroxime Axetil 500Mg Tab
35 Microbiologic Findings of Acute Facial Palsy in Children Completed NCT01537952
36 Doxycycline in Therapy of Erythema Migrans Completed NCT01475708 Doxycycline
37 Study of Anti-HIV Therapy Intensification Completed NCT00034086 Not Applicable Lopinavir/Ritonavir;Lamivudine/Zidovudine;Tenofovir disoproxil fumarate;Lamivudine;Stavudine;Zidovudine;Didanosine
38 Duration of Antibiotic Treatment of Erythema Migrans Completed NCT00910715 Not Applicable doxycycline;doxycycline;placebo
39 Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) Completed NCT01766830 Not Applicable
40 Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel Recruiting NCT03581279 Not Applicable
41 Next Generation Sequencing Detection of Lyme Disease Recruiting NCT03505879
42 Evaluation, Treatment, and Follow-up of Patients With Lyme Disease Recruiting NCT00028080
43 A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations Recruiting NCT00001539
44 Borrelia Species in Cutaneous Lyme Borreliosis Recruiting NCT00576082
45 Understanding Tick-borne Diseases Recruiting NCT03501407
46 Characteristics of Lyme Arthritis Recruiting NCT03510507
47 Patient's Pretreatment Expectations About Post-Lyme Symptoms Recruiting NCT03462329 Not Applicable Antibiotics (preferentially oral doxycycline 100 mg bid)
48 Lyme Borreliosis and Early Cutaneous Diagnostic Recruiting NCT02414789 Not Applicable
49 Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health Recruiting NCT02669212
50 Screening for the Transthyretin-Related Familial Amyloidotic Small Fiber Polyneuropathy Recruiting NCT01705626

Search NIH Clinical Center for Lyme Disease

Cochrane evidence based reviews: lyme disease

Genetic Tests for Lyme Disease

Anatomical Context for Lyme Disease

MalaCards organs/tissues related to Lyme Disease:

41
Testes, Skin, Heart, Eye, T Cells, B Cells, Brain

Publications for Lyme Disease

Articles related to Lyme Disease:

(show top 50) (show all 2289)
# Title Authors Year
1
Cost-effectiveness of a potential anti-tick vaccine with combined protection against Lyme borreliosis and tick-borne encephalitis in Slovenia. ( 30197268 )
2019
2
Interventions to prevent Lyme disease in humans: A systematic review. ( 30456054 )
2019
3
Public health and patient safety concerns merit retention of Lyme borreliosis-associated spirochetes within the genus Borrelia, and rejection of the genus novum Borreliella. ( 30154058 )
2019
4
Revisiting the Lyme Disease Serodiagnostic Algorithm: The Momentum Gathers. ( 29898997 )
2018
5
Insights from the Geographic Spread of the Lyme Disease Epidemic. ( 29920580 )
2018
6
Humanizing the digital revolution, the secret life of yeast and Lyme disease through a climate lens: Books in brief. ( 29446403 )
2018
7
Amblyomma americanum (Acari: Ixodidae) Ticks Are Not Vectors of the Lyme Disease Agent, Borrelia burgdorferi (Spirocheatales: Spirochaetaceae): A Review of the Evidence. ( 29394366 )
2018
8
Ticks transmitting Lyme disease are found in a third of Britain, mainly the south. ( 29440061 )
2018
9
Sleep Quality in Well-defined Lyme Disease: A Clinical Cohort Study in Maryland. ( 29452400 )
2018
10
Development and Validation of a Serologic Test Panel for Detection of Powassan Virus Infection in U.S. Patients Residing in Regions Where Lyme Disease Is Endemic. ( 29359181 )
2018
11
Lyme disease surveillance in the United States: Looking for ways to cut the Gordian knot. ( 29431297 )
2018
12
Cognitive Decline in Post-treatment Lyme Disease Syndrome. ( 29945190 )
2018
13
Obstacles to diagnosis and treatment of Lyme disease in the USA: a qualitative study. ( 29895655 )
2018
14
Identification of surface epitopes associated with protection against highly immune-evasive VlsE-expressing Lyme disease spirochetes. ( 29866906 )
2018
15
Catching up with Lyme Disease Antigenic Variation Computationally. ( 29903419 )
2018
16
Lyme disease presenting with multiple cranial neuropathies on MRI. ( 29942765 )
2018
17
Obsessive-compulsive symptoms in adults with Lyme disease. ( 29408088 )
2018
18
Of ignorance and blindness: The Lyme disease paradigm. ( 29805049 )
2018
19
Exploring an alternative approach to Lyme disease surveillance in Maryland. ( 29411541 )
2018
20
Relative Risk for Ehrlichiosis and Lyme Disease Where Vectors for Both Are Sympatric, Southeastern United States. ( 29350157 )
2018
21
Exacerbation of chronic pain after dental extractions in a patient with post-treatment Lyme disease syndrome. ( 29416466 )
2018
22
Multiflora rose invasion amplifies prevalence of Lyme disease pathogen, but not necessarily Lyme disease risk. ( 29361971 )
2018
23
Clinical manifestations of reported Lyme disease cases in Ontario, Canada: 2005-2014. ( 29856831 )
2018
24
Serologic Evidence of Tick-Borne Encephalitis Virus Infection in a Patient with Suspected Lyme Disease in Japan. ( 29848409 )
2018
25
The Financial Implications of a Well-Hidden and Ignored Chronic Lyme Disease Pandemic. ( 29438352 )
2018
26
Correction to: Development of a sensitive PCR-dot blot assay to supplement serological tests for diagnosing Lyme disease. ( 29404837 )
2018
27
An Unusual Cluster of Neuroinvasive Lyme Disease Cases Presenting With Bannwarth Syndrome in the Midwest United States. ( 29383323 )
2018
28
Lyme Disease Testing in a High-Incidence State: Clinician Knowledge and Patterns. ( 29425271 )
2018
29
Incidence of Lyme Disease Diagnosis in a Maryland Medicaid Population, 2004-2011. ( 29955850 )
2018
30
Detecting the Lyme Disease Spirochete, Borrelia Burgdorferi, in Ticks Using Nested PCR. ( 29443061 )
2018
31
Recognizing Lyme Disease. ( 29957621 )
2018
32
Tick borne illness-Lyme disease. ( 29402399 )
2018
33
<i>Ixodes</i> Immune Responses Against Lyme Disease Pathogens. ( 29896452 )
2018
34
Motivations and Experiences of Canadians Seeking Treatment for Lyme Disease Outside of the Conventional Canadian Health-Care System. ( 29978028 )
2018
35
Improvement of common variable immunodeficiency using embryonic stem cell therapy in a patient with lyme disease: a clinical case report. ( 29881587 )
2018
36
A Community Study of <i>Borrelia burgdorferi</i> Antibodies among Individuals with Prior Lyme Disease in Endemic Areas. ( 29921784 )
2018
37
Borrelia burgdorferi in small mammal reservoirs in Kentucky, a traditionally non-endemic state for Lyme disease. ( 29417273 )
2018
38
The oligopeptide ABC transporter OppA4 negatively regulates the virulence factor OspC production of the Lyme disease pathogen. ( 29921537 )
2018
39
Acrodermatitis chronica atrophicans: various faces of the late form of Lyme borreliosis. ( 30429707 )
2018
40
Adult-onset Still's disease with haemorrhagic pericarditis and tamponade preceded by acute Lyme disease. ( 30115716 )
2018
41
Babesiosis and Lyme Disease in a 68-year-old man. ( 30068051 )
2018
42
Notes from the Field: Reference Laboratory Investigation of Patients with Clinically Diagnosed Lyme Disease and Babesiosis - Indiana, 2016. ( 30335739 )
2018
43
Investigating disease severity in an animal model of concurrent babesiosis and Lyme disease. ( 30367867 )
2018
44
C-Reactive Protein Response in Patients With Post-Treatment Lyme Disease Symptoms Versus Those With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. ( 29741589 )
2018
45
Frontotemporal Dementia Misdiagnosed for Post-Treatment Lyme Disease Syndrome or vice versa? A Treviso Dementia (TREDEM) Registry Case Report. ( 30282363 )
2018
46
The Emergence of a Forgotten Entity: Dermatomyositis-like Presentation of Lyme Disease in Rural Wisconsin. ( 30013872 )
2018
47
Large-scale health disparities associated with Lyme disease and human monocytic ehrlichiosis in the United States, 2007-2013. ( 30261027 )
2018
48
Lyme borreliosis as a trigger for NMDA receptor encephalitis? ( 30008117 )
2018
49
Neuroborreliosis and acute encephalopathy: The use of CXCL13 as a biomarker in CNS manifestations of Lyme borreliosis. ( 29246814 )
2018
50
Pediatric Bilateral Facial Paralysis: An Unusual Presentation of Lyme Disease. ( 30365410 )
2018

Variations for Lyme Disease

Expression for Lyme Disease

Search GEO for disease gene expression data for Lyme Disease.

Pathways for Lyme Disease

Pathways related to Lyme Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 C3 CD40LG CFH CRP IL17A IL1B
2
Show member pathways
13.4 CD40LG IL17A IL1B IL6 TLR1 TLR2
3
Show member pathways
13.06 C3 IL1B IL6 MMP9 TLR2 TNF
4
Show member pathways
13 C3 IL1B IL6 TLR1 TLR2 TLR6
5
Show member pathways
12.85 C3 CD40LG HSPD1 IL17A IL1B IL6
6
Show member pathways
12.79 C3 IL1B IL6 TLR2 TNF
7
Show member pathways
12.7 CD40LG IL1B IL6 TLR1 TLR2 TLR6
8
Show member pathways
12.63 CD40LG IL1B TLR1 TLR2 TLR6 TNF
9
Show member pathways
12.61 IL17A IL1B IL6 TLR2 TNF
10
Show member pathways
12.56 IL17A IL1B IL6 TNF
11 12.52 CD40LG IL17A IL1B TLR1 TLR2 TLR6
12
Show member pathways
12.45 CD40LG IL17A IL1B IL6 TNF
13
Show member pathways
12.34 CRP IL1B IL6 TNF
14
Show member pathways
12.33 IL17A IL1B IL6 MMP9 TLR2 TNF
15
Show member pathways
12.28 IL6 TLR1 TLR2 TLR6 TNF
16
Show member pathways
12.26 C3 CD40LG IL1B TLR2 TNF
17
Show member pathways
12.24 IL1B IL6 TLR2 TNF
18
Show member pathways
12.24 CLDN11 IL1B MMP9 TLR1 TLR2 TLR6
19
Show member pathways
12.23 IL17A IL1B IL6 TNF
20 12.2 HSPD1 IL1B IL6 TNF
21
Show member pathways
12.13 IL1B IL6 TLR1 TLR2 TLR6 TNF
22 12.1 IL6 MMP9 TLR1 TLR2 TLR6 TNF
23
Show member pathways
12.06 IL1B TLR1 TLR2 TLR6
24 12.04 IL1B IL6 MMP9 TNF
25 12.01 IL17A IL1B IL6 MMP9 TNF
26 11.99 IL1B IL6 MMP9 TNF
27 11.92 IL1B IL6 TLR2 TNF
28
Show member pathways
11.91 IL17A IL1B IL6 TLR1 TLR2 TLR6
29 11.89 IL1B IL6 TNF
30 11.88 IL1B IL6 TNF
31 11.87 CD40LG IL1B TNF
32 11.86 C3 TLR1 TLR2 TLR6
33 11.86 IL17A IL1B IL6 TLR2 TNF
34 11.81 C3 HSPD1 IL1B IL6 TLR1 TLR2
35 11.79 IL17A IL1B TNF
36 11.79 C3 IL1B IL6 TNF
37 11.75 IL1B IL6 TNF
38 11.73 IL17A IL1B IL6 MMP9 TNF
39 11.68 IL1B IL6 MMP9 TNF
41
Show member pathways
11.57 CD40LG IL1B IL6 MMP9 TNF
42 11.56 IL1B IL6 TNF
43 11.55 IL6 MMP9 TNF
44 11.54 IL1B TLR2 TNF
45 11.51 IL1B IL6 TNF
46 11.41 CD40LG IL1B IL6 TLR2 TNF
47 11.4 IL1B IL6 TNF
48 11.39 IL1B IL6 TNF
49 11.37 C3 HSPD1 IL1B IL6 TLR2 TNF
50 11.35 IL17A IL1B IL6 TNF

GO Terms for Lyme Disease

Cellular components related to Lyme Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 C3 CD40LG CFH CFHR1 CRP IL17A
2 membrane raft GO:0045121 9.55 HSPD1 TLR1 TLR2 TLR6 TNF
3 phagocytic vesicle membrane GO:0030670 9.5 TLR1 TLR2 TLR6
4 extracellular space GO:0005615 9.36 C3 CD40LG CFH CFHR1 CRP HSPD1
5 Toll-like receptor 1-Toll-like receptor 2 protein complex GO:0035354 9.26 TLR1 TLR2

Biological processes related to Lyme Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.99 C3 IL1B MMP9 TNF
2 positive regulation of gene expression GO:0010628 9.99 CRP IL1B IL6 TLR2 TLR6 TNF
3 positive regulation of DNA-binding transcription factor activity GO:0051091 9.9 IL1B IL6 TNF
4 regulation of complement activation GO:0030449 9.89 C3 CFH CFHR1
5 complement activation GO:0006956 9.89 C3 CFH CFHR1
6 positive regulation of inflammatory response GO:0050729 9.88 HSPD1 TLR2 TNF
7 positive regulation of T cell proliferation GO:0042102 9.87 CD40LG IL1B IL6
8 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.87 IL1B TLR2 TNF
9 positive regulation of interferon-gamma production GO:0032729 9.86 HSPD1 IL1B TNF
10 defense response to Gram-positive bacterium GO:0050830 9.86 CRP IL6 TLR2 TNF
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.84 IL1B TLR6 TNF
12 positive regulation of JUN kinase activity GO:0043507 9.84 IL1B TLR6 TNF
13 positive regulation of phagocytosis GO:0050766 9.83 C3 IL1B TNF
14 toll-like receptor signaling pathway GO:0002224 9.83 TLR1 TLR2 TLR6
15 lipopolysaccharide-mediated signaling pathway GO:0031663 9.81 IL1B TLR2 TNF
16 response to glucocorticoid GO:0051384 9.8 HSPD1 IL1B IL6 TNF
17 positive regulation of interleukin-8 production GO:0032757 9.78 IL1B TLR2 TNF
18 negative regulation of neurogenesis GO:0050768 9.77 IL1B IL6 TNF
19 positive regulation of interleukin-12 production GO:0032735 9.77 CD40LG HSPD1 TLR2
20 positive regulation of interleukin-6 secretion GO:2000778 9.76 HSPD1 IL17A IL1B
21 positive regulation of interleukin-10 production GO:0032733 9.74 CD40LG HSPD1 TLR2
22 negative regulation of lipid catabolic process GO:0050995 9.73 IL1B TNF
23 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.73 IL17A TLR6
24 positive regulation of macrophage activation GO:0043032 9.73 HSPD1 TLR6
25 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.72 IL1B TNF
26 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.72 IL1B TNF
27 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.72 IL1B TNF
28 positive regulation of chemokine production GO:0032722 9.72 IL6 TLR2 TNF
29 positive regulation of interleukin-8 secretion GO:2000484 9.71 TLR1 TLR2
30 complement activation, alternative pathway GO:0006957 9.71 C3 CFH
31 microglial cell activation GO:0001774 9.71 TLR2 TLR6 TNF
32 positive regulation of chemokine biosynthetic process GO:0045080 9.7 IL1B TNF
33 regulation of establishment of endothelial barrier GO:1903140 9.7 IL1B TNF
34 positive regulation of glial cell proliferation GO:0060252 9.7 IL1B IL6 TNF
35 positive regulation of fever generation GO:0031622 9.69 IL1B TNF
36 regulation of immunoglobulin secretion GO:0051023 9.69 CD40LG TNF
37 cellular response to diacyl bacterial lipopeptide GO:0071726 9.68 TLR2 TLR6
38 chronic inflammatory response to antigenic stimulus GO:0002439 9.68 IL1B TNF
39 sequestering of triglyceride GO:0030730 9.67 IL1B TNF
40 toll-like receptor TLR6:TLR2 signaling pathway GO:0038124 9.67 TLR2 TLR6
41 cellular response to triacyl bacterial lipopeptide GO:0071727 9.65 TLR1 TLR2
42 nitric oxide metabolic process GO:0046209 9.65 TLR2 TLR6
43 regulation of cytokine secretion GO:0050707 9.65 TLR1 TLR2 TLR6
44 positive regulation of interleukin-6 production GO:0032755 9.65 HSPD1 IL1B IL6 TLR2 TNF
45 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.64 IL1B TNF
46 toll-like receptor TLR1:TLR2 signaling pathway GO:0038123 9.64 TLR1 TLR2
47 cell activation GO:0001775 9.63 TLR1 TLR2 TLR6
48 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.63 CD40LG IL1B IL6 TLR2 TLR6 TNF
49 detection of diacyl bacterial lipopeptide GO:0042496 9.62 TLR2 TLR6
50 detection of triacyl bacterial lipopeptide GO:0042495 9.62 TLR1 TLR2

Molecular functions related to Lyme Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.87 CLDN11 CRP MMP9 TLR1 TLR2 TLR6
2 protein binding GO:0005515 9.86 C3 CD40LG CFH CFHR1 CLDN11 CRP
3 protein heterodimerization activity GO:0046982 9.77 CFHR1 HSPD1 TLR1 TLR2 TLR6
4 cytokine activity GO:0005125 9.55 CD40LG IL17A IL1B IL6 TNF
5 Toll-like receptor 2 binding GO:0035663 9.26 TLR1 TLR6
6 lipopeptide binding GO:0071723 8.8 TLR1 TLR2 TLR6

Sources for Lyme Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....